• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Disparities in time to treatment with oral antimyeloma medications

by | Aug 24, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

by | Aug 19, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

A roadmap towards improving outcomes in multiple myeloma

by | Aug 12, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm

by | Aug 12, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma

by | Aug 9, 2024 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Isatuximab Shows Promise in Enhancing PFS for Patients with Multiple Myeloma

by | Aug 8, 2024 | Myeloma News

Source: Pharmacy Times articles Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma. Read More
« Older Entries
Next Entries »

Recent Content

  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT